Overview

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to demonstrate that the use of Gleevec in initially non-resectable gastrointestinal stromal tumors can lead to allow complete resection in 20% of cases.
Phase:
Phase 2
Details
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborator:
Hippocrate Research & Development
Treatments:
Imatinib Mesylate